Page 5 - Ipid Management News Today

"Its a new antibody that has a long half-life so each treatment can be prolonged."

Age-related increases in pulmonary artery systolic pressure occur in concert with worsening left ventricular diastolic dysfunction and contribute to late-life dyspnea, new data show.

The first-in-human HEART-1 trial of in vivo DNA editing called VERVE-101, shows reductions in LDL and PCSK9 protein in patients with familial hypercholesterolemia.

For 1 in 4 patients with primary biliary cholangitis (PBC) who received the investigational PPAR-delta agonist, alkaline phosphatase levels normalized.

Up to half of RA patients in the United States use long-term glucocorticoids despite previous work suggesting they increase MACE in a dose-dependent way.

In two studies run in parallel, testing different strategies, automatic referral to a pharmacist was superior to EHR alerts for increasing statin prescriptions for at-risk patients.

Though some may still consider it to be pseudoscience, the positive data behind social connection is hard to deny. And its easy for physicians to push.

In an early phase multicenter study, reductions in lipoprotein(a) to undetectable levels were achieved with a small interfering RNA therapeutic, lepodisiran.

A first-of-its-kind study aimed to determine if treating age-related hearing loss could prevent cognitive decline.

Even if you struggle to give exercise advice to your patients, this simple starter guide can help (including things NOT to say).